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ABSTRACT
Gliomas are lethal brain tumors that resist standard therapeutic approaches. Immunotherapy is a promising
alternative strategy mostly developed in the context of glioblastoma. However, there is a need for
implementing immunotherapy for grade II/III gliomas, as these are the most common CNS tumors in young
adults with a high propensity for recurrence, making them lethal despite current treatments. We recently
identified HLA-A2-restricted tumor-associated antigens by peptide elution from glioblastoma and formulated
a multipeptide vaccine (IMA950) evaluated in phase I/II clinical trials with promising results. Here, we
investigated expression of the IMA950 antigens in patients with grade II/III astrocytoma, oligodendroglioma
or ependymoma, at the mRNA, protein and peptide levels. We report that the BCAN, CSPG4, IGF2BP3,
PTPRZ1 and TNC proteins are significantly over-expressed at the mRNA (n D 159) and protein (n D 36) levels
in grade II/III glioma patients as compared to non-tumor samples (IGF2BP3 being absent from
oligodendroglioma). Most importantly, we detected spontaneous antigen-specific T cell responses to one or
more of the IMA950 antigens in 100% and 71% of grade II and grade III patients, respectively (27 patients
tested). These patients displayed T cell responses of better quality (higher frequency, broader epitope
targeting) than patients with glioblastoma. Detection of spontaneous T cell responses to the IMA950
antigens shows that these antigens are relevant for tumor targeting, which will be best achieved by
combination with CD4 epitopes such as the IDH1R132H peptide. Altogether, we provide the rationale for
using a selective set of IMA950 peptides for vaccination of patients with grade II/III glioma.
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Introduction
WHO grade II and III glioma include astrocytoma, oligodendro-
glioma and ependymoma and are the most common central ner-
vous system (CNS) tumors in young adults. Grade II and III
astrocytoma almost inevitably evolve to secondary glioblastoma
(grade IV), a disease associated with very poor prognosis.1,2
Tumors deriving from ependymal cells (i.e. ependymoma) are
rarer but some of them display a similar poor prognosis,3,4 advocat-
ing for alternative therapeutic strategies. One of the pillars of cancer
therapy is immunotherapy, with the recent development of
immune checkpoint inhibitors that have the potential to synergize
with cell therapy and cancer vaccines.5,6 Among vaccines, most of
them have targeted glioblastoma (GBM) so far, most likely due to
the limited knowledge about antigen expression by grade II/III
tumors. However, recent studies of peptide vaccines in grade II gli-
oma patients showed promising results7,8 and additional trials are
ongoing, including one with a peptide spanning the IDH1R132H
mutation found in themajority of low-grade glioma and secondary
GBM (sGBM).9
Implementing vaccines as complementary treatments for
patients with grade II/III glioma is a very attractive strategy
considering the characteristics of these incurable tumors.
Indeed, even when gross total resection is achieved, they
ultimately relapse due to their impressive invasive proper-
ties, and/or transform into high-grade tumors.10,11 In addi-
tion quality of life is often worsened by the tumor itself, its
progression, or the side effects related to the different
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treatments.12,13 Finally, grade II/III glioma patients have a
longer life expectancy than grade IV patients, may receive
less concomitant treatments (at least for grade II) and seem
to face less systemic immunosuppression, offering more
time to elicit strong and long-lasting anti-tumor immune
responses. Therefore, vaccines have the theoretical potential
to achieve valuable clinical benefit, such as delaying tumor
progression, transformation, or improving quality of life,
autonomy and maintaining social inclusion.
We recently identified nine glioma-associated antigens by
peptide elution from the surface of HLA-A0201C GBM
samples which were overexpressed on tumor versus normal
tissues, detected in a majority of patients and which were
immunogenic.14 These antigens, together with two HLA class
II-restricted peptides, have been formulated in a multipep-
tide vaccine (called IMA950), which was shown to be well
tolerated and immunogenic in combination with GM-CSF15
and is currently being tested in combination with poly-ICLC
(NCT01920191).16 Here, in order to broaden the use of vac-
cines to grade II and III glioma patients, we investigated
expression of the IMA950 antigens (which encompasses pep-
tides derived from the BCAN, CSPG4, FABP7, IGF2BP3,
NLGN4X, NRCAM, PTPRZ1 and TNC proteins), as well as
additional glioma- or melanoma-associated antigens (gp100,
Her2, IL13Ra2, SOX2 and TRP2) in a series of patients pre-
senting with grade II or III astrocytoma, oligodendroglioma
and ependymoma, at the mRNA (n D 159), protein (n D 36)
and peptide (n D 6) levels. In addition, we explored the
presence of spontaneous T cell responses to these antigens in
patients with grade II and III glioma.
Results
Most of glioma-associated antigens identified in grade IV
tumors are expressed in grade II and III glioma
We analysed mRNA expression levels of the antigens targeted
by the IMA950 vaccine (Supplementary Table S1) in grade II
(n D 49) and grade III (n D 41) astrocytoma, grade II (n D 30)
and grade III (n D 27) oligodendroglioma and ependymoma
(n D 12) using the Nanostring nCounter technology (probesets
are listed in Supplementary Table S2). The IMA950 vaccine
incorporates 9 HLA-A2-restricted tumor-eluted peptides
derived from BCAN, CSPG4, FABP7, IGF2BP3, NLGN4X,
NRCAM, PTPRZ1 (2 peptides) and TNC (Supplementary
Table S1). Expression of gp100, Her2, IL13Ra, SOX2 and TRP2
was also analyzed as these antigens were shown to be overex-
pressed in GBM and/or melanoma and HLA-A2-restricted
peptides recognized by T cells have been described.17–20 We
also included 29 de novo and 16 s GBM samples as well as 12
non-tumor brain samples (8 epilepsy samples, 2 post-mortem
brain samples and 2 commercial brain RNA) as controls.
Expression of BCAN at the mRNA level among all samples
tested is shown as a representative example in Fig. 1A. Box plot
analysis shows that BCAN mRNA is significantly upregulated as
compared to non-tumor samples in grade II and III astrocytoma,
Figure 1. BCAN RNA expression on grade II, III astrocytoma, oligodendroglioma and ependymoma samples. (A) RNA counts using the Nanostring technology for the BCAN
gene. Tumor samples are grouped by type and non-tumor control samples (8 epilepsy samples, 2 normal brains, 2 commercial RNAs) are shown on the right (ctrl).
sGBM: secondary GBM. (B) Box plots analysis of expression of the BCAN gene on the different tumor groups showing the median, lower quartile (25th percentile) and upper
quartile (75th percentile). The bars indicate the lower adjacent value and the upper adjacent value. Points indicate outliers. AII: grade II astrocytoma, AIII: grade III astrocytoma,
ODII: grade II oligodendroglioma, ODIII: grade III oligodendroglioma, EP: ependymoma, sGBM: secondary GBM, ctrl: non-tumor samples. : p < 0.01, : p < 0.05.
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grade II and III oligodendroglioma, ependymoma, sGBM and de
novo GBM14 (Fig. 1B, p < 0.01 for all comparisons except epen-
dymoma: p < 0.05). Analysis of all target antigens revealed that
five of them (i.e., BCAN, CSPG4, PTPRZ1, TNC and SOX2)
were significantly overexpressed in all tumor groups as compared
to the non-tumoral control samples (Fig. 2A). IGF2BP3 was
overexpressed in grade II and III astrocytoma and grade IV sam-
ples (Fig. 2B). FABP7 was upregulated in grade IV tumors only.
Furthermore, gp100, Her2, IL13Ra and TPR2 were mainly upre-
gulated in ependymoma whilst only TRP2 was significantly upre-
gulated in grade II/III astrocytoma samples (Fig. 2D). The
NLGN4X and NRCAM genes were detected at similar levels in
control and tumor samples (except for ependymoma, Fig. 2C).
Finally, we did not observe significant differential expression of
any gene between grade II and grade III astrocytoma or oligo-
dendroglioma (Fig. 2A-2D); BCAN was significantly decreased
in primary GBM as compared to all other tumors (P < 0.01 for
all comparisons).
Interestingly, we were able to analyze paired samples
obtained from the same patient at primary surgery and pro-
gression, with or without change to higher grade. We observed
that progression from grade II or III glioma to sGBM was asso-
ciated with a significant increase in expression of the IGF2BP3
gene (p < 0.05, Fig. 2E), whereas no significant difference was
observed for the other genes (data not shown). This was consis-
tent with overexpression of IGF2BP3 in GBM when all (includ-
ing non-paired) samples were considered (Fig. 2B).
We next then determined the percentage of positive sam-
ples within each tumor type, taking the percentage of samples
with mRNA counts higher than the mean C 2 standard devia-
tions of mRNA counts in non-tumor samples as the cutoff.
As shown in Fig. 3, the BCAN, PTPRZ1, TNC21 and SOX2
gene mRNA were over-expressed in the majority of astrocy-
toma, oligodendroglioma and ependymoma samples tested
(with the exception of PTPRZ1, which was expressed in 20%
of ependymoma only). Expression of the CSPG4, FABP7,
Figure 2. Antigen expression on grade II, III astrocytoma, oligodendroglioma and ependymoma samples and recurrent sample pairs. Box plots analysis of expression of
the BCAN, CSPG4, PTPRZ1, TNC and SOX2 (A), FABP7 and IGF2BP3 (B), NLGN4X and NRCAM (C), IL13Ra2, gp100, Her2 and TRP2 (D) genes on the different tumor groups
showing the median, lower quartile (25th percentile) and upper quartile (75th percentile). The bars indicate the lower adjacent value and the upper adjacent value.
: p < 0.05 versus non-tumor samples, : p < 0.01 versus non-tumor samples.. AII: grade II astrocytoma, AIII: grade III astrocytoma, ODII: grade II oligodendroglioma,
ODIII: grade III oligodendroglioma, EP: ependymoma, sGBM: secondary GBM, ctrl: non-tumor samples. (E) mRNA counts for the IGF2BP3 gene in paired (pairs of 2, 3 or 4,
each separated by a space) recurrent samples. AIIèAII: grade II astrocytoma recurring as grade II astrocytoma, AIIèAIII: grade II astrocytoma recurring as grade III astro-
cytoma, AIIèsGBM: grade II astrocytoma recurring as secondary GBM, AIIIèsGBM: grade III astrocytoma recurring as secondary GBM.
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IGF2BP3, gp100, Her2, IL13Ra2 and TRP2 genes was more
heterogeneous. The percentage of NLGN4X- or NRCAM-pos-
itive tumors was low. In order to get appraisal of gene expres-
sion within individual tumor types, the same data were
plotted per tumor type (Supplementary Figure S1) and data
obtained for all genes and tumor groups summarized in
Supplementary Table S3.
IMA950 antigens are detected at the protein and peptide
levels in grade II/III glioma
Confirmation of antigen expression at the protein level was per-
formed for the IMA950 antigens using a tissue microarray inco-
rporating 24 grade II and 12 grade III astrocytoma samples22 (see
representative examples in Fig. 4A). The BCAN, CSPG4, FABP7,
IGF2BP3 and NLGN4X, NRCAM and PTPRZ1 proteins were
detected in grade II and II astrocytoma samples as well as in
sGBM. Expression of TNC and SOX2 was previously reported.21,23
Importantly, these proteins were expressed in the majority (>80%)
of grade II and III astrocytoma samples tested (Fig. 4B), suggesting
that the majority of patients may benefit from vaccination with the
IMA950-derived antigens.
In order to further ensure cell surface presentation of the
IMA950 antigenic peptides, we submitted grade II (n D 2) and
III (n D 4) astrocytoma and grade II (n D 2) and III (n D 1)
oligodendroglioma samples from HLA-A2C patients to peptide
elution and identification. Normal tissues as well as de novo GBM
samples were used for comparison of peptide presentation levels.
Three samples (2 grade II astrocytoma and 1 grade II oligoden-
droglioma) yielded very few (<400) peptides and were not further
analyzed. Shown as an example (Fig. 4C), the PTPRZ1195-203 pep-
tide was detected in the one remaining grade II samples and in
the 5 analyzable grade III samples, whereas it was detected at very
low levels in a small subset of normal tissue samples only. The
mass spectrometry signal intensity (reflecting amount of peptide
presentation at the cell surface) of the PTPRZ1195-203 peptide was
similar in grade II/III and GBM samples (p D 0.42). This was the
case also for the CSPG421-29, PTPRZ11347-1355 and TNC3-11 pepti-
des (supplementary Figure S2). The FABP7118-126 peptide was
detected in one sample only whereas the BCAN478-486,
IGF2BP3552-560, NLGN4X131-139 and NRCAM692-700 peptides were
not detected in these samples.
The majority of patients with grade II/III glioma display
spontaneous immune responses to the IMA950 antigens
In order to determine if such pre-existing T cell responses also exist
in patients with grade II/III tumors, we incubated PBMC with a
cocktail of the IMA950HLA-A2-binding peptides and assessed the
presence of specific T cells by MHC/peptide multimer staining
Figure 3. Proportion of positive samples for the tested antigens. Percentage of samples positive for BCAN, CSPG4, FABP7, IGF2BP3, NLGN4X, NRCAM, PTPRZ1, TNC, gp100,
Her2, IL13Ra2, SOX2 and TRP2, determined as mRNA counts>mean mRNA counts for non-tumor samplesC 2 standard deviations. AII: grade II astrocytoma, AIII: grade III
astrocytoma, ODII: grade II oligodendroglioma, ODIII: grade III oligodendroglioma, EP: ependymoma, sGBM: secondary GBM, ctrl: non-tumor samples (hatched bars).
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after one week of culture. HLA-A2C patients with grade II astrocy-
toma (nD 8), grade II oligodendroglioma (nD 2), grade III astro-
cytoma (n D 14), grade III oligodendroglioma (n D 3) and
primary GBM (n D 17) were tested. The majority of patients with
grade II or grade III (100% and 71%, respectively) glioma displayed
specific immune responses to one or more of the IMA950 antigens
(representative examples in Fig. 5A), with occasionally highmagni-
tude of CD8C T cells detected. In addition, as shown in Fig. 5B for a
grade II astrocytoma patient, CD8 T cell responses to more than
one peptide (up to 5) were detected in 60% and 47% of patients
with grade II or III tumors, respectively (Fig. 5C). Importantly,
detection of T cell response to multiple (>3) peptides was greater
in patients with grade II and III tumors as compared with patients
with GBM (Fig. 5C). This was not due to the intrinsic inability of T
cells isolated from patients withGBM to proliferate, as proliferation
assays to CD3/CD28 beads showed no differences in proliferation
capacity between patients with grade II, III or IV tumors (12
patients were tested per group, data not shown).
Discussion
Glioma vaccines are being investigated for many years and the
recent successful development of CTLA-4 and PD-1 antibodies
is likely to give them a new impetus.24 To date, peptide vaccines
have been developed mostly for grade IV tumors but are now
slowly being implemented for grade II/III glioma. One study
showed induction of robust and poly-epitopic T cell responses
in grade II astrocytoma/oligoastrocytoma patients after vacci-
nation with a cocktail of four glioma-associated antigens
(EphA2, WT1, IL13Ra2 and survivin in Montanide) adju-
vanted with poly-ICLC.7 The same peptide cocktail (excluding
WT1) was tested in paediatric patients with recurrent low-
grade glioma25 and a phase II study in the same patient
population is ongoing (NCT02358187). Further studies using a
peptide spanning the IDH1R132H mutation in IDH1 mutated
grade II/III/IV astrocytoma patients (NCT02193347 and
NCT02454634) are ongoing and will provide useful informa-
tion on the potential of peptide vaccines in grade II/III glioma.
The present results contribute to this field as they provide a
detailed analysis of the expression profile of nine antigens com-
posing the IMA950 vaccine in grade II/III astrocytoma and oli-
godendroglioma patients. We show that the BCAN, CSPG4,
IGF2BP3, PTPRZ1 and TNC proteins are significantly over-
expressed at the mRNA and protein levels in grade II/III glioma
patients as compared to non-tumor samples (IGF2BP3 being
absent from oligodendroglioma), making peptides derived
from these proteins candidates for therapeutic vaccination for
these patients. Importantly, the majority (>50%) of grade II/III
patients had tumors positive for BCAN, PTPRZ1 and TNC and
20–50% of them displayed expression of CSPG4 and IGF2BP3.
Adding the latter antigens to the multipeptide vaccine is of
importance to target all tumor cells and avoid tumor escape by
antigen downregulation.26
Regarding NLGN4X and NRCAM, data are less definitive.
Despite a high mRNA level in grade II/III glioma and GBM,
NLGN4X and NRCAM were not overexpressed as compared to
non-tumor samples. These results were confirmed in qPCR
analysis (Supplementary Figure S3), suggesting that these two
gene mRNAs are expressed at significant levels in normal brain
tissues. However, we previously showed that the peptides
derived from the NLGN4X and NRCAM proteins are detected
at the surface of GBM cells but not non-tumor brain cells, pos-
sibly due to different protein processing and presentation by
tumor cells.14 This discrepancy between mRNA expression lev-
els and peptide presentation at the cell surface is not unex-
pected and has been specifically investigated.27 It was shown
Figure 4. Expression of IMA950 antigens at the protein and peptide levels. (A) Representative IHC staining for the BCAN, CSPG4, FABP7 and IGF2BP3 proteins on grade II
and III astrocytoma and secondary GBM (sGBM). Inserts show higher magnification. Bar scale: 100 mm (B) Percentage of positive tumors. (C) Presentation of the
PTPRZ1195-203 peptide at the surface of normal samples including normal brain samples, grade II/III samples and GBM. Upper panel: Shown is the MS signal intensity,
reflecting peptide presentation at the cell surface, including box plots analysis showing the median, lower quartile (25th percentile) and upper quartile (75th percentile).
The box plot bars indicate the lower adjacent value and the upper adjacent value. Lower panel: peptide detection frequency on the tested tissues.
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that a significant number of peptides presented predominantly
showed no or only minor changes in mRNA expression level.
Therefore, absence of increased mRNA levels does not imply
that these peptides are absent from the surface of grade II/III
glioma samples. To address this important issue, available
grade II and III glioma samples were analyzed by liquid
chromatography and mass spectrometry. We could detect five
of the IMA950 peptides (CSPG421-29, IGF2BP3552-560,
PTPRZ1195-203, PTPRZ11347-1355 and TNC3-11). These peptides
were presented at a level comparable to that observed for
GBM and at higher levels as compared to normal brain sam-
ples. Their detection ensures that these peptides can function
as antigens recognized by T cells, a level of analysis usually
not attained for other glioma-associated antigens, for which
immune responses induced upon vaccination might prove
inefficient due to lack of the cognate target. The other pepti-
des, including those derived from the NLGN4X and NRCAM
proteins, were not detected. The low number of samples
available for such an analysis could explain these results.
Indeed, elution of a sufficient number of peptides for sensitive
analysis requires large samples with high tumor content, two
parameters that are not always obtained concomitantly
despite extended surgery in grade II/III glioma.
On the other hand, the detection of NLGN4X-specific T cell
responses in patients with grade II/III tumors suggests that the
tumor elicited a response to this peptide. The presence of small
amounts of peptide, below the detection limit of liquid chroma-
tography-mass spectrometry technologies used for peptide elu-
tion, might be enough to trigger a T cell response in vivo.28
Additionally, we previously showed in vitro that NLGN4X was
one of the most immunogenic peptides composing the IMA950
vaccine,14 suggesting that potent NLGN4X-specific T cell
responses elicited upon vaccination will be able to detect small
amounts of peptide in vivo. Nevertheless, although the
NLGN4X and NRCAM peptides are interesting targets for vac-
cine implementation in grade II/III glioma, we recommend
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Figure 5. Spontaneous T cell responses to the IMA950 antigens are detected in patients with grade II/III tumors. (A) Representative examples of T cell responses in four
different grade II/III astrocytoma (Ge 939, Ge 135, Ge 299)/oligodendroglioma (Ge 398) patients specific for 5 different antigens. The number of CD8C HLA-A2/peptide
tetramerC T cells are shown in the upper right quadrant. (B) T cell responses towards 3 different antigens are shown for grade II astrocytoma patient Ge 570. The number
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and primary GBM (nD 17) patients with spontaneous T cell responses to 0, 1, 2, 3 or more antigens. (D) Pattern of spontaneous T cell responses in grade II, III astrocytoma
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waiting for peptide presentation data to be available before
inclusion in vaccination protocols. Regarding the other pepti-
des (BCAN478-486, CSPG421-29, IGF2BP3552-560, PTPRZ1195-203,
PTPRZ11347-1355 and TNC3-11), mRNA expression and peptide
presentation data provide evidence for their use in a therapeutic
peptide vaccine, taking as well into account the absence of pep-
tide-specific autoimmune adverse events observed in clinical
trials investigating the use of the IMA950 antigens in GBM.15,16
Expression of gp100, Her2, IL13Ra,7,29,30 SOX2 and TRP231
was analyzed as these antigens were shown to be overexpressed in
GBM and/or melanoma and HLA-A2-restricted peptides recog-
nized by T cells are available for potential vaccination.17–20 Only
SOX2 displayed strong over-expression in grade II/III astrocy-
toma/oligodendroglioma and ependymoma, with > 80% positive
samples. An HLA-A2-resticted SOX2-derived peptide (SOX2118-
127) eliciting glioma-specific T cells has been described
20 and future
knowledge of presentation of SOX-2-derived peptides at the sur-
face of grade II/III glioma could promote its use together with the
selected IMA950 peptides in future vaccination trials.
In this study, we had the opportunity to study a few cases of
ependymoma, a rare and heterogeneous tumor with variable
responses to treatment. Immunotherapeutic strategies are start-
ing to being developed for this disease,32,33 based on the obser-
vations that ependymoma is infiltrated by immune cells34 and
that this correlates with good prognosis in pediatric patients.35
Our results offer new targets for this tumor entity. IMA950
antigen expression in ependymoma was somewhat different as
compared to astrocytoma and oligodendroglioma, with TNC
being expressed in almost 90% of samples, an observation
which is not surprising given the cell of origin of this malig-
nancy.36 We observed a constant downregulation of NLGN4X
and NRCAM in ependymoma samples tested, whereas other
studies associated NRCAM with highly-proliferative ependy-
moma37 We also detected high levels of Her2 expression at the
mRNA level in this group of patients, but analysis of protein
expression did not display increased expression as compared to
normal brain tissues (not shown). Although the number of
samples studied here is limited, our results offer new antigens
for the study of ependymoma. Only a few HLA-A2C patients
(n D 4) with ependymoma were available for investigating the
presence of spontaneous T cell responses to the IMA950 anti-
gens. Among these, two patients displayed low but detectable T
cell responses to the BCAN478-486 and PTPRZ11347-1355 antigens
(not shown), suggesting that, although further analysis is
needed, patients with ependymoma might as well be able to
mount spontaneous antitumor immune responses.14
The detection of spontaneous (i.e. not induced by vaccina-
tion) CD8 T cell responses to several IMA950 antigens in grade
II and III glioma patients further supports the use of these anti-
gens in a therapeutic vaccine. Spontaneous T cell responses to
glioma-associated antigens have previously been reported in
one grade III astrocytoma patient38; our observations now fur-
ther indicate that these responses are frequent and directed
towards multiple glioma-associated antigens in patients with
grade II/III astrocytoma and oligodendroglioma. Interestingly,
patients with grade II/III tumors displayed T cell responses of
better quality than patients with GBM, as determined by a
higher frequency and a broader epitope targeting. This might
reflect the fact that patients with grade II/III tumors are less
immunosuppressed as compared to patients with grade IV
tumors, suggesting that vaccination in this patient population
could be more efficient.
Based on the results obtained in this study, we propose to
use selected peptides from the IMA950 vaccine depending on
the tumor type. Patients suffering from grade II/III astrocytoma
or from ependymoma would receive a vaccine composed of the
BCAN478-486, CSPG421-29, IGF2BP3552-560, PTPRZ1195-203,
PTPRZ11347-1355 and TNC3-11 peptides, whereas patients suffer-
ing from oligodendroglioma would be vaccinated with
BCAN478-486, CSPG421-29, PTPRZ1195-203, PTPRZ11347-1355 and
TNC3-11 (supplementary Figure S4). The majority of samples
used in this study having been collected over the last 20 years,
the IDH1/2 mutation as well as the 1p/19q LOH status are not
available for most of the samples. Although worth investigating,
expression of the antigens examined in this study is unlikely to
correlate with the molecular profile of the tumor. Importantly,
these vaccines would benefit from combination with HLA-DR-
restricted epitopes, such as those currently included in the
IMA950 vaccine (Supplementary Table S1) but, more interest-
ingly, with the glioma-specific IDH1R132H mutant peptide
mentioned above.9 There is indeed considerable evidence for
the crucial need to integrate both CD4 and CD8 T cell
responses in designing immunotherapies.39–42 Due to the high
frequency of the IDH1 mutation in patients with grade II/III
glioma,1 the IDH1R132H-derived CD4 peptide is the epitope
of choice to integrate with the herein-described CD8 T cell
antigens. Furthermore, the fact that spontaneous T cell
responses to both the IDH1R132H CD4 epitope9 and to the
IMA950 CD8 antigens are detected suggests that tolerance to
these antigens has not been induced and opens the possibility
of further augmenting the magnitude of the response to see
whether antitumor effector function can be achieved through
vaccination in combination with immune checkpoint inhibitors
or molecules targeting the tumor microenvironment. Finally, in
the light of the results of the recent trials of adoptive transfer of
GBM-specific chimeric antigen receptor T cells,43–46 our results
indicate that adoptive transfer of TCR-transgenic T cells spe-
cific for the epitopes we describe in this study would be an
additional attractive approach to explore. These rationally
designed trials will hopefully improve progression-free survival,
life expectancy and quality of life of patients suffering from
grade II/III glioma.
Methods
Patients and samples
Two-hundred and fourteen patients were included in this
study, which conformed to the ethical guidelines of the 1975
Declaration of Helsinki and was approved by the Institutional
Review Board of all centers involved. All patients gave written
informed consent. Patients with grade II (n D 49), III (n D 41)
astrocytoma, grade II (n D 30) and III (n D 27) oligodendro-
glioma, primary (n D 29) and secondary GBM (n D 16), epen-
dymoma (n D 12), and patients with epilepsy (n D 8) were
seen at the Geneva University Hospital, University of Heidel-
berg and the Tumor Research Centre in San Francisco. Tumor
or epilepsy samples were collected at time of initial or recurrent
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surgery. Initial surgery was performed prior to any radiothera-
peutic or chemotherapeutic treatment. Ependymoma were
obtained from all grades (grade I, II and III: 4, 6 and 2 patients,
respectively). Tumor and epilepsy samples were processed
immediately and frozen in liquid nitrogen for further analysis.
Normal brain samples (n D 2) were obtained from cadaveric
brain donation from GBM patients in the Geneva University
Hospital after informed consent and processed similarly. They
were taken at distance from the tumor site and confirmed by
the pathologist to be tumor-free. sGBM samples were all pro-
gression from astrocytoma except for two samples that were
progression from oligodendroglioma. Two commercial brain
RNA samples (Amsbio 1 whole brain ref R1234035-P, 1 cere-
bellum, ref R1234039-50) were purchased.
RNA isolation
Tumor tissues were homogenized and RNA extraction was per-
formed using an RNEasy Mini Kit (Qiagen, ref 74104). RNA
quality was tested using a BioAnalyzer (Agilent Technologies)
and quantified using a spectrophotometer. When necessary,
DNase (Sigma, ref AMPD1-1KT) treatment was performed to
remove contaminating DNA.
qPCR analysis
Expression of the BCAN, NLGN4X and NRCAM genes was
verified by qPCR. Two pairs of primers per gene (Supplemen-
tary Table S4) were designed, one covering the Nanostring pro-
besets (primers_n) and one matching that used in Affymetrix
HG-U13314 (primers_a). Housekeeping genes used were
GAPDH, GusB and TBP. Eight tumor as well as 8 non-tumor
(CD8 sorted T cells, 2 commercial brain RNA, 1 post-mortem
brain and 4 epilepsy) samples were tested.
Tissue microarray and immunohistochemistry
The tissue microarray contained 24 astrocytoma grade II
and 12 astrocytoma grade III as well as four normal brain
samples as described.22 Informed consent was obtained
from each patient according to the research proposals
approved by the Institutional Review Board at Heidelberg
Medical Faculty. Antigen retrieval, incubation with primary
and secondary antibodies as well as detection with VEC-
TASTAIN Laboratories Elite ABC Kit (Vector Laboratories,
ref PK-6100) was carried out as described.22 Each tumor
biopsy was evaluated at x20 magnification by two indepen-
dent investigators.
Peptide elution from brain specimens
Nine HLA-A0201C tumor biopsies samples were analysed and
compared to a panel of 244 non-tumoral body tissue including
7 brain tissues. Shock-frozen tumor samples were essentially
processed as described previously47 according to standard pro-
tocols.48 Briefly, HLA-A02 peptide pools from shock-frozen
tissue samples were obtained by immune precipitation from
solid tissue using HLA-specific antibodies, acid treatment and
ultrafiltration. To obtain samples containing HLA-A02-
restricted peptides the antibody BB7.2 was used.49 The HLA
peptide pools as obtained were separated according to their
hydrophobicity by reversed-phase chromatography (nanoAcq-
uity UPLC system, Waters) and the eluted peptides were ana-
lysed in an LTQ Orbitrap hybrid mass spectrometer (Thermo
Fisher Scientific) equipped with an electrospray ionization
source. The LC–MS data were collected and automatically
processed by analyzing the LC–MS survey (mass signals of
unfragmented peptides) as well as the tandem-MS (MS/MS)
data (fragment spectra containing peptide sequence informa-
tion). Automated data analysis had been optimized and
adapted for identification and quantification of HLA-restricted
peptides.
Assessment of spontaneous antigen-specific immune
responses
HLA-A2C patients with grade II, III and IV astrocytoma
(including sGBM) or grade II and III oligodendroglioma were
selected for analysis of spontaneous T cell responses to the
IMA950 antigens. The majority of patients were sampled at the
time of tumor resection. Nine patients (3 grade II, 3 grade III,
3 GBM patients) had received temozolomide and/or radiother-
apy more than 3 years before PBMC sampling and 10 patients
(2 grade II, 3 grade III and 5 GBM patients) were under or less
than 3 months away from treatment with either chemotherapy
or radiotherapy. PBMC (5 £ 106) were incubated with a mix of
the IMA950 peptides (BCAN478-486 ALWAWPSEL; CSPG421-29
TMLARLASA; FABP7118-126 LTFGDVVAV; IGF2BP3552-560
KIQEILTQV; NLGN4X131-139 NLDTLMTYV; NRCAM692-700
GLWHHQTEV; PTPRZ1195-203 AIIDGVESV; PTPRZ11347-1355
KVFAGIPTV; TNC3-11 AMTQLLAGV, 1 mM each) for 7 days
in the presence of 100 IU/ml IL-2 (Proleukine, Novartis) before
staining with MHC/peptide tetramers (kindly provided by
Immatics Biotechnologies GmbH, Germany) and CD8 (Beck-
man Coulter, ref 6607102). Dead cells were excluded using a
Live/Dead dye (Invitrogen, ref L34959). In order to assess tetra-
mer background and set a threshold for positive tetramer stain-
ing, we analyzed nine HLA-A2 negative patients suffering from
grade II (n D 2), III (n D 4) or IV (n D 3) tumors with the
same protocol. A tetramer staining was considered positive if (i)
the number of tetramerCCD8C T cells observed in flow cytome-
try was >20, (ii) the percentage of tetramerC CD8C T cells was
superior to the mean percentage of tetramerCCD8C T cells in
HLA-A2 negative individuals C 2 SD, (iii) the median of
tetramerCCD8C T cells was superior to the median of
tetramerCCD8C T cells in HLA-A2 negative individuals C 2 SD.
Statistical analysis
Differentially expressed genes (tumors vs. ctrl, recurrent vs. pri-
mary and astrocytoma vs. secondary GBM) were identified by
using the marker selection feature of GENE-E (http://www.
broadinstitute.org/cancer/software/GENE-E/index.html). Dif-
ference in expression between the classes was calculated using a
t-test that estimates the significance (permutation p-values) of
the test score. It was then corrected for multiple hypotheses
testing (MHT) by computing the false discovery rate (FDR).
FDR was estimated using the Benjamini and Hochberg
e1391972-8 V. DUTOIT ET AL.
procedure.50 Correlation coefficients were considered signifi-
cant when p-value <0.01.
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